Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Leuk Res. 2017 Nov 11;64:30–33. doi: 10.1016/j.leukres.2017.11.004

Figure 3. Inhibition of CDK1 or CDK1 and CDK2 Reduces the Combinatorial Effect of AZD1775 and Cytarabine.

Figure 3

A. Relative numbers of viable Jurkat cells treated with DMSO (vehicle control), AZD1775 (200 nM), RO-3306 (2.5 uM), and/or Ara-C (10 nM) for 72 hr. Viable cell counts are normalized to cells receiving no treatment (NT). Results are shown as mean ± SEM from three independent experiments. **, P < 0.01. B and C. Relative numbers of viable Jurkat (B) or MV4;11 (C) cells treated with DMSO (vehicle control), AZD1775 (200 nM), roscovitine (10 uM), and/or Ara-C (10 nM) for 72 hr. Viable cell counts are normalized to cells receiving no treatment (NT). Results are shown as mean ± SEM from three independent experiments. *, P < 0.05. **, P < 0.01. ***, P < 0.001. D. Jurkat cells were treated with the indicated doses of roscovitine, AZD1775, and/or Ara-C for 24 hr after which protein lysates were subjected to western blotting with antibodies specific to PARP and actin.